Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosrolapitant + palonosetron hydrochloride + dexamethasone acetate
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Fosrolapitant + palonosetron hydrochloride + dexamethasone acetate is a triple-combination antiemetic regimen developed for the prevention of chemotherapy-induced nausea and vomiting (CINV). The regimen consists of HR20013—a fixed-dose intravenous combination of fosrolapitant (a prodrug of the neurokinin-1/NK1 receptor antagonist rolapitant) and palonosetron hydrochloride (a selective 5-HT3 receptor antagonist)—administered alongside the corticosteroid dexamethasone acetate. By simultaneously antagonizing NK1 and 5-HT3 receptors and activating glucocorticoid receptors, this combination targets multiple emetic pathways to prevent both acute and delayed phases of nausea and vomiting. It is primarily being evaluated in patients receiving highly or moderately emetogenic chemotherapy, including those with esophageal and lung cancer.
- Other names
- Fosrolapitant and Palonosetron Hydrochloride for Injection combined with dexamethasone acetate
02
Targets
GR (Glucocorticoid receptor)HTR3A (5-hydroxytryptamine receptor 3A)TACR1 (Neurokinin‑1 Receptor)
Beyond the preview
Go deeper on fosrolapitant + palonosetron hydrochloride + dexamethasone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosrolapitant + palonosetron hydrochloride + dexamethasone acetate.